First Trust Advisors LP lessened its holdings in shares of Inogen Inc (NASDAQ:INGN) by 29.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,900 shares of the medical technology company’s stock after selling 7,551 shares during the quarter. First Trust Advisors LP owned about 0.09% of Inogen worth $2,132,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also modified their holdings of the company. Lenox Wealth Advisors Inc. acquired a new stake in shares of Inogen during the fourth quarter worth about $100,000. Steward Partners Investment Advisory LLC lifted its position in shares of Inogen by 1,000.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock worth $130,000 after purchasing an additional 1,000 shares in the last quarter. Simplex Trading LLC acquired a new stake in shares of Inogen during the fourth quarter worth about $153,000. LS Investment Advisors LLC lifted its position in shares of Inogen by 138.6% during the fourth quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock worth $180,000 after purchasing an additional 880 shares in the last quarter. Finally, Everence Capital Management Inc. acquired a new stake in shares of Inogen during the fourth quarter worth about $208,000. 99.45% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently issued reports on INGN. Zacks Investment Research cut shares of Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. BidaskClub raised shares of Inogen from a “sell” rating to a “hold” rating in a research report on Wednesday, January 24th. Piper Jaffray Companies raised shares of Inogen from a “neutral” rating to an “overweight” rating in a research report on Tuesday, February 20th. Finally, Needham & Company LLC increased their price target on shares of Inogen from $125.00 to $150.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $107.29.
In related news, Director Ray Benjamin M. Anderson sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $119.06, for a total value of $119,060.00. Following the sale, the director now owns 1,000 shares of the company’s stock, valued at $119,060. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Alison Bauerlein sold 11,718 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $115.87, for a total transaction of $1,357,764.66. Following the completion of the sale, the chief financial officer now directly owns 11,718 shares in the company, valued at approximately $1,357,764.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 159,369 shares of company stock worth $19,038,125. 5.31% of the stock is owned by corporate insiders.
Shares of Inogen Inc (INGN) opened at $125.02 on Tuesday. The firm has a market cap of $2,723.18, a P/E ratio of 100.07, a P/E/G ratio of 3.59 and a beta of 1.03. Inogen Inc has a 1-year low of $73.68 and a 1-year high of $134.97.
TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/03/20/inogen-inc-ingn-holdings-reduced-by-first-trust-advisors-lp.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.